Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • aangs94
    Junior Member
    • Feb 2013
    • 4

    #1

    Two Fastq files from a same patient with 2 technologies : When combine ?

    Hi everyone,

    I have datas from a patient sequenced two years ago and now I have datas from the SAME patient re-sequenced last month with a different technology.
    Both are exomes.

    Maybe some people had the same case, but if I want to do a combine analysis (SNP calling), when do I have to combine the two files ?
    1/ concatenate the FASTQ files and then proceed to analysis of the unique file
    OR
    2/ combine each BAM files (cleaned or not) for examples or any further files?

    If somebody had already done this kind of analysis, or maybe any publication with such examples...It will help me a lot.

    Thanks very much to the NGS community.
  • swbarnes2
    Senior Member
    • May 2008
    • 910

    #2
    I don't think combining the fastqs is a good idea. Two different technologies will have there own error profiles, I don't think analysis software is designed to work with that. For instance, Illumina is not prone to homopolymer errors, but 454 is. So if you combined the two together, you might think you have a mixed indel in a homopolymer region, where examination of the Illumina data alone would show you that the 454 was causing that artifact. I think the right thing to do is to use whatever SNP calling program is best for each technology, then compare your results after that point. So don't merge fasts or bams, but vcfs.

    Comment

    • aangs94
      Junior Member
      • Feb 2013
      • 4

      #3
      re

      an
      Originally posted by swbarnes2 View Post
      I don't think combining the fastqs is a good idea. Two different technologies will have there own error profiles, I don't think analysis software is designed to work with that. For instance, Illumina is not prone to homopolymer errors, but 454 is. So if you combined the two together, you might think you have a mixed indel in a homopolymer region, where examination of the Illumina data alone would show you that the 454 was causing that artifact. I think the right thing to do is to use whatever SNP calling program is best for each technology, then compare your results after that point. So don't merge fasts or bams, but vcfs.
      Thanks very much swbarnes2 for your clear answer.

      I think you are right. If I can ask you one more thing :
      what if the same sample is sequenced two times with the same technology but in separate dates (for example one year difference)?, is it ok if I merge the fastq files or the bam files (like a biological or technical replicate)? I imagine it could improve the depth or coverage?

      Comment

      • swbarnes2
        Senior Member
        • May 2008
        • 910

        #4
        Assess the overall quality of the two datasets. Looks at % of base >=Q30, something like that. Do they look like they are in the ballpark of being equally good quality?

        Then I'd align them separately, and look at the flagstat figures, or something like that. Do the alignments look like they are about the same quality?

        If that's the case, merge the .bams, and call SNPs from that. That'll be better than calling SNPs on them apart.

        Comment

        • aangs94
          Junior Member
          • Feb 2013
          • 4

          #5
          Thanks very much swbarnes2, very efficient!!

          Ok, so if the two fastq files are equivalent in term of quality, I start the analysis pipeline until the flagstat figure. Then merge the .bams.
          Do you think that merging cleaned or unclead bams may have an impact at this step ?

          Tks again

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            10-14-2026, 09:55 AM
          • SEQadmin2
            New Genomics Technologies Take Aim at Long-Standing Limits
            by SEQadmin2


            Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

            We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
            ...
            09-28-2026, 10:25 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 10-22-2026, 11:13 AM
          0 responses
          36 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 10:48 AM
          0 responses
          28 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-15-2026, 10:52 AM
          0 responses
          41 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-14-2026, 05:39 AM
          0 responses
          45 views
          0 reactions
          Last Post SEQadmin2  
          Working...